Announced new data demonstrating a unique mechanism of action supporting the best-in-class potential of rademikibart – – Recruitment ongoing for Phase 1b study of intravenously-administered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback